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ABSTRACT
Objective: To evaluate the current use of Australian
Type 2 Diabetes Risk Assessment Tool (AUSDRISK) as
a screening tool to identify individuals at high risk of
developing type 2 diabetes for entry into lifestyle
modification programs.
Research Design and Methods: AUSDRISK scores
were calculated from participants aged 40–74 years in
the Greater Green Triangle Risk Factor Study, a cross-
sectional population survey in 3 regions of Southwest
Victoria, Australia, 2004–2006. Biomedical profiles of
AUSDRISK risk categories were determined along with
estimates of the Victorian population included at
various cut-off scores. Sensitivity, specificity, positive
predictive value (PPV), negative predictive value, and
receiver operating characteristics were calculated for
AUSDRISK in determining fasting plasma glucose
(FPG) ≥6.1 mmol/L.
Results: Increasing AUSDRISK scores were associated
with an increase in weight, body mass index, FPG, and
metabolic syndrome. Increasing the minimum cut-off
score also increased the proportion of individuals who
were obese and centrally obese, had impaired fasting
glucose (IFG) and metabolic syndrome. An AUSDRISK
score of ≥12 was estimated to include 39.5% of the
Victorian population aged 40–74 (916 000), while a
score of ≥20 would include only 5.2% of the same
population (120 000). At AUSDRISK≥20, the PPV for
detecting FPG≥6.1 mmol/L was 28.4%.
Conclusions: AUSDRISK is powered to predict those
with IFG and undiagnosed type 2 diabetes, but its
effectiveness as the sole determinant for entry into a
lifestyle modification program is questionable given the
large proportion of the population screened-in using the
current minimum cut-off of ≥12. AUSDRISK should be
used in conjunction with oral glucose tolerance testing,
fasting glucose, or glycated hemoglobin to identify
those individuals at highest risk of progression to type 2
diabetes, who should be the primary targets for lifestyle
modification.
INTRODUCTION
The incidence of type 2 diabetes mellitus is
rising globally and the prevalence in
Australia is estimated to reach over 2.3
million by 2035.1 Annual expenditure on dia-
betes in Australia already amounts to over A
$14 billion in direct costs and government
subsidies,2 therefore population and high-
risk strategies are required to mitigate future
disease burden.
A number of studies aimed at prevention
of type 2 diabetes have included only those
with disorders of abnormal glucose metabol-
ism.3–5 Individuals with impaired glucose tol-
erance (IGT) and impaired fasting glucose
(IFG), are among the highest risk for devel-
oping type 2 diabetes, with an annual inci-
dence of 5–10% across various categories of
IGT or IFG.6 Such disorders are reversible,
and trials have demonstrated that intensive
lifestyle modiﬁcation programs can success-
fully halt or delay progression to type 2 dia-
betes in high-risk groups.3–5
On the basis of the results of these rando-
mized trials, and the national demonstrator
Greater Green Triangle Diabetes Prevention
Program (DPP),7 along with economic mod-
eling, the Council of Australian Governments
in 2006 decided to invest in lifestyle modiﬁ-
cation programs for diabetes prevention.
Key messages
▪ Type 2 diabetes risk assessment tools should be
used in conjunction with fasting glucose, oral
glucose tolerance testing, or glycated hemoglo-
bin to determine entry into lifestyle modification
programs.
▪ Cut-off scores of type 2 diabetes risk assess-
ment tools for screening into lifestyle modifica-
tion programs and further testing should be
chosen with knowledge of the proportion of the
population at different risk scores.
▪ Lowering entry criteria for lifestyle modification
programs to reduce risk of type 2 diabetes is
likely to decrease the impact of the program as
well as the cost-effectiveness.
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The Federal Government’s program was targeted at
adults aged 40–49 years, and the state and territory pro-
grams targeted those aged 50 years and over. National
standards for lifestyle modiﬁcation programs were
agreed on, and work started on an Australian tool for
risk assessment (Australian Type 2 Diabetes Risk
Assessment Tool, AUSDRISK)8 9 to reﬂect the ethnic
diversity of the contemporary Australian population.10
AUSDRISK is a 10-item questionnaire that estimates risk
of progression to type 2 diabetes over 5 years. Its scoring
includes questions based on age, sex, ethnicity, family
history of diabetes, history of abnormal glucose metabol-
ism, smoking status, current hypertensive treatment,
physical activity, fruit and vegetable consumption, and
waist circumference.
The Federal DPP was discontinued in 2011 due to
poor recruitment and other implementation pro-
blems.11 The Victorian Life! program is a statewide DPP
established by Diabetes Australia–Victoria in 2007.12
AUSDRISK was chosen as the screening tool for Life!,
with an entry score of ≥15 initially selected, but low
recruitment rates led to a decision to lower the entry
score to ≥12.13 The Australian experience with
AUSDRISK will be relevant to other countries wanting
to develop a national instrument for screening.
Many other risk tools have been developed and vali-
dated to predict risk of type 2 diabetes, both in terms of
current and future risk. These tools have been demon-
strated to be effective and cost-effective in identiﬁcation
of individuals at high risk of developing type 2 diabetes,
though their effectiveness may vary across different
populations.14 Using a questionnaire such as AUSDRISK
is a practical method to screen for high-risk individuals
who might beneﬁt from lifestyle modiﬁcation, but it has
been recommended that those found to be at high risk
should also undergo an oral glucose tolerance test
(OGTT) or glycated hemoglobin (HbA1c) to determine
impairment of glucose metabolism and screen for
undiagnosed diabetes.15 16 Those found to have abnor-
mal glucose metabolism should be invited to participate
in lifestyle modiﬁcation programs, while those with
normal glucose metabolism should be provided with life-
style advice and reassessed in 2–3 years.15–17
Best practice for recruitment and screening of indivi-
duals into real-world DPP remains uncertain. Given this
knowledge gap and the implications for the effectiveness
and cost-effectiveness, this paper evaluates the perform-
ance of AUSDRISK in identifying suitable candidates for
entry into lifestyle modiﬁcation programs.
RESEARCH DESIGN AND METHODS
Sampling and collection
The Greater Green Triangle Risk Factor Study (GGT
RFS) consisted of three cross-sectional surveys of chronic
disease risk factors carried out in Southwest Victoria
from 2003 to 2006. This data set was chosen as the
survey instrument had good agreement with biomedical
and lifestyle questions relevant to AUSDRISK. Collection
of data has been reported previously.18 19
Inclusion and exclusion criteria
Data from survey respondents aged 40–74 years were
included for calculating AUSDRISK scores. Individuals
who self-reported a previous diagnosis of diabetes,
history of treatment with insulin, oral hypoglycemics or
both were excluded from the analysis. Those with fasting
plasma glucose (FPG) >6.9 mmol/L were included in
the study in order to evaluate the ability of AUSDRISK
to detect those with undiagnosed diabetes in addition to
IFG.
All participants had age and sex data available as they
were selected from the electoral roll. Participants who
did not have a waist circumference measurement were
excluded from analysis, as a score could not be reliably
imputed from the survey data.
Treatment of missing values
For AUSDRISK questions not related to waist circumfer-
ence, missing values were assumed to score zero. A sensi-
tivity analysis comparing total risk scores was undertaken
with missing values imputed as zero versus cases
excluded if there was at least one missing value.
Conversion of data into risk scores
Survey responses were coded into scores for AUSDRISK
from the GGT RFS. Where survey questions did not dir-
ectly match those of the screening tool, either the most
similar question or a combination of questions was used
to infer the most likely response. For example, in
AUSDRISK question eight related to fruit and vegetable
consumption, respondents were considered to score 0
(eat fruit everyday) if they reported eating vegetables or
fruit 5–6 times per week or more.
Definition of IFG and MetS
The WHO deﬁnition of IFG (6.1–6.9 mmol/L) was
used.20 The metabolic syndrome (MetS) was deﬁned as
per International Diabetes Federation (IDF) criteria,21
with individuals required to have central obesity
(deﬁned by waist circumference with ethnicity speciﬁc
values) plus any two of the following risk factors for
diagnosis: raised triglycerides (≥1.7 mmol/L), reduced
high-density lipoprotein cholesterol (males, <1.03;
females, <1.29 mmol/L), raised blood pressure (systolic
BP≥130 or diastolic BP≥85 mm Hg) or raised FPG
(≥5.6 mmol/L).
Statistical analyses
All analyses were performed in Stata V.13. Crude base-
line demographic and biomedical measures were
reported as mean values and SDs. Risk score stratiﬁca-
tions were selected according to their reported risks of
developing type 2 diabetes.9 Annual incidence of type 2
diabetes for AUSDRISK categories was estimated using
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the reported risk of progression over 5 years assuming a
constant yearly risk.
Proportions of the sample population were stratiﬁed
by risk score, sex and age group. Estimates of the popu-
lation in Victoria, Australia, were made at different
cut-off scores using the estimated resident population in
Victoria at 30 June 2014.22 Sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive value
were calculated for FPG≥6.1 mmol/L and stratiﬁed by
risk score. Receiver operating characteristics (ROC) are
also presented.
RESULTS
Of 1690 respondents in the GGT RFS, 1393 fulﬁlled age
criteria. Of those, 129 were excluded due to lack of waist
circumference measurements and a further 75 were
omitted due to established diagnosis of diabetes, its
treatment, or both. There was no signiﬁcant difference
between mean AUSDRISK scores when missing values
were imputed as zero versus cases with missing values
excluded from analysis. The results reported here are
for those where missing values were assumed to score
zero. Overall, AUSDRISK scores were calculated for
1189 individuals. Males were older than females and
comprised a smaller proportion of the overall sample
(table 1).
Overall, IFG prevalence was 4.7% (males 6.7%;
females 2.9%). Mean body mass index (BMI) was similar
in the overweight range for both genders (table 1). The
MetS was present in 40.5% of males and 32.6% of
females. Diabetic and cardiovascular risk factors, except
total and low-density lipoprotein cholesterol, and also
the presence of MetS demonstrated a signiﬁcant linear
trend when stratiﬁed by AUSDRISK group according to
approximate risk of progression to diabetes (table 2).
Use of higher cut-off scores demonstrated increases in
mean values of key diabetic risk factors (weight, BMI,
waist circumference, FPG) (table 3).
The proportion of individuals included at different
AUSDRISK cut-offs increased with age (table 4). Nearly
40% of the Victorian population aged 40–74 years was
estimated to have an AUSDRISK score of 12 or more,
falling to approximately 5.2% at a cut-off score of 20 or
higher (table 4).
After an AUSDRISK cut-off of ≥14, the sum of sensitiv-
ity and speciﬁcity for detecting FPG≥6.1 mmol/L began
to decline (table 5). ROC for detecting FPG≥6.1 mmol/L
was 0.76 (95% CI 0.70 to 0.81).
DISCUSSION
Apart from the original Australian Diabetes, Obesity and
Lifestyle study from which AUSDRISK was created,8 to
the best of our knowledge, our study is the ﬁrst that
applies a detailed analysis of the risk tool to an
Australian population to deﬁne different risk categories.
We have evaluated AUSDRISK as a screening tool for
lifestyle modiﬁcation programs in Australia and found
some important limitations that have international impli-
cations for policy and cost-effectiveness of such pro-
grams. Increases in AUSDRISK score categories were
accompanied by increases in key biological risk factors
for type 2 diabetes (table 2). Accordingly, using higher
cut-off scores resulted in a higher proportion of indivi-
duals with obesity, central obesity, IFG and the MetS.
These ﬁndings highlight the need to select a strategy for
screening individuals into lifestyle modiﬁcation pro-
grams to ensure that those who will beneﬁt most are
recruited.
For countries wishing to develop a national DPP, to
determine the cut-off points for screening tools requires
knowledge of the proportion of the population that will
screen positive, and a minimum entry score should be
selected to identify a feasible proportion of the popula-
tion it is intended to reach (table 4). Based on our esti-
mates, the current requirement of AUSDRISK≥12 would
translate into 39.5% (916 000) of Victorians aged 40–
74 years being eligible to participate in the Life!
program. Increasing the minimum score to ≥20 reduces
this proportion to 5.2% (120 000). Using previously
reported prevalence of IGT (13.0%) and IFG (7.4%)
in Australia among adults aged 40–74 years,23
Table 1 Characteristics of GGT RFS sample aged
40–74 years with a calculated AUSDRISK score
Variable N Mean (SD)
Males
Age (years) 561 58.2 (9.5)
Weight (kg) 560 87.6 (16.1)
BMI (kg/m²) 560 28.5 (4.9)
Waist circumference (cm) 561 100.4 (12.7)
FPG (mmol/L) 519 5.4 (0.6)
Total cholesterol (mmol/L) 547 5.4 (1.0)
HDL (mmol/L) 547 1.3 (0.4)
LDL (mmol/L) 534 3.3 (0.9)
Triglycerides (mmol/L) 547 1.7 (1.1)
Systolic BP (mm Hg) 561 135.2 (19.0)
Diastolic BP (mm Hg) 561 80.5 (10.8)
AUSDRISK value 561 12.9 (4.5)
Females
Age (years) 628 56.9 (9.5)
Weight (kg) 628 74.9 (16.1)
BMI (kg/m²) 625 28.5 (6.1)
Waist circumference (cm) 628 89.8 (14.3)
FPG (mmol/L) 586 5.2 (0.5)
Total cholesterol (mmol/L) 600 5.6 (1.0)
HDL (mmol/L) 600 1.6 (0.4)
LDL (mmol/L) 597 3.3 (1.0)
Triglycerides (mmol/L) 600 1.5 (0.7)
Systolic BP (mm Hg) 628 131.1 (19.7)
Diastolic BP (mm Hg) 626 75.4 (10.6)
AUSDRISK value 628 10.3 (4.7)
AUSDRISK, Australian Type 2 Diabetes Risk Assessment Tool;
BMI, body mass index; BP, blood pressure; FPG, fasting plasma
glucose; GGT RFS, Greater Green Triangle Risk Factor Study;
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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approximately 154 000 and 87 000 Victorians in this age
group would be expected to have IGT and IFG, respect-
ively. From 2007 to 2011, Life! received 29 000 referrals
with 8412 initiating the program, and 3114 completed
session 1 and session 6.12 Life! was recently reported to
have received an updated total of 59 000 referrals.24
Given these numbers, the impact of the Life! program
has likely been diluted by targeting those at compara-
tively lower risk of developing type 2 diabetes
(ie, AUSDRISK≥12), and would have a greater impact if
delivered exclusively to those with abnormal glucose
metabolism.
As the prevalence of IFG in our sample (4.7%) and
the Australian population23 is relatively low, even at a
cut-off of AUSDRISK≥20, the PPV for detecting
FPG≥6.1 mmol/L was 28.4%. Although 2 h postglucose
load data was not collected in this study, with the preva-
lence of IGT or IFG previously estimated at 16.4%,23 the
expected PPV for detecting IGT or IFG would be slightly
greater than that for IFG alone. These results demon-
strate that a diabetes risk assessment tool alone cannot
be used to determine glucose metabolism status, and
additional testing with OGTT, fasting glucose, or HbA1c
is required for those who are identiﬁed to be at elevated
risk of progressing to type 2 diabetes, as suggested by
international guidelines.15 16 Previous research has also
demonstrated that this two-stage screening strategy is a
more cost-effective method to identify individuals with
undiagnosed diabetes, IFG and IGT than laboratory
testing alone.25 Even though clinicians may opt to
proceed directly to laboratory testing, setting an appro-
priate and cost-effective cut-off score for entry to lifestyle
modiﬁcation programs is important, given that Life! has
seen a signiﬁcant proportion of individuals recruited
through a variety of methods not involving physicians or
other health professionals.12
Early involvement of family physicians represents an
important opportunity to identify additional comorbid-
ities and chronic disease risk factors. Our results demon-
strate that a signiﬁcant proportion of individuals at high
risk of progressing to type 2 diabetes also have key car-
diovascular risk factors including hypertension, hyper-
cholesterolemia, and MetS (table 3). Previous research
has demonstrated the existence of treatment gaps in
treatment of hypertension and dyslipidemia among
those participating in lifestyle modiﬁcation programs.26
Table 2 Diabetic and cardiovascular risk factors in GGT RFS by sex and AUSDRISK category
AUSDRISK category
0–5 6–8 9–11 12–15 16–19 20–36
Annual incidence of type 2 diabetes (%) 0.2 0.4 0.7 1.5 3.0 7.8
Males
Number of observations (%) 10 (1.8) 77 (13.7) 180 (32.1) 134 (23.9) 107 (19.1) 53 (9.5)
Age (years) 41.8 47.8 57.2 61.0 61.5 65.5
Weight (kg) 87.7 81.5 81.6 84.5 97.2 105.1
BMI (kg/m2) 27.9 26.1 26.6 27.6 31.5 34.6
Waist circumference (cm) 92.2 91.6 94.4 98.8 110.6 118.8
FPG (mmol/L) 5.2 5.2 5.2 5.3 5.6 5.8
Total cholesterol (mmol/L) 5.2 5.7 5.6 5.4 5.1 5.0
HDL (mmol/L) 1.4 1.4 1.4 1.3 1.2 1.2
LDL (mmol/L) 3.2 3.6 3.5 3.3 3.1 2.9
Triglycerides (mmol/L) 1.3 1.5 1.6 1.7 1.9 2.0
Systolic BP (mm Hg) 120.4 124.5 130.2 137.2 143.2 149.3
Diastolic BP (mm Hg) 79.3 80.3 79.3 79.4 82.4 84.0
MetS (%) 11.1 14.7 26.8 41.6 64.9 83.3
Females
Number of observations (%) 98 (15.6) 161 (25.6) 117 (18.6) 154 (24.5) 75 (11.9) 23 (3.7)
Age (years) 46.3 56.1 56.7 61.3 61.6 65.0
Weight (kg) 65.2 67.5 74.1 80.0 88.8 92.4
BMI (kg/m2) 24.2 25.6 28.1 30.7 34.0 36.5
Waist circumference (cm) 77.8 81.6 88.0 96.9 104.6 113.2
FPG (mmol/L) 4.9 5.0 5.1 5.2 5.5 5.7
Total cholesterol (mmol/L) 5.1 5.8 5.5 5.9 5.5 5.3
HDL (mmol/L) 1.8 1.8 1.6 1.6 1.4 1.4
LDL (mmol/L) 2.8 3.4 3.2 3.5 3.2 3.1
Triglycerides (mmol/L) 1.0 1.2 1.5 1.8 1.9 1.9
Systolic BP (mm Hg) 117.0 126.3 132.0 137.8 141.1 141.2
Diastolic BP (mm Hg) 71.7 74.3 77.3 76.7 77.8 73.4
MetS (%) 4.4 11.8 28.3 53.1 64.7 89.5
AUSDRISK, Australian Type 2 Diabetes Risk Assessment Tool; BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose;
GGT RFS, Greater Green Triangle Risk Factor Study; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MetS, metabolic syndrome.
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Therefore, in addition to lifestyle modiﬁcation, addres-
sing these risk factors is essential to reducing future
disease burden, as cardiovascular disease contributes dis-
proportionately to the morbidity as a result of
diabetes.27
The baseline risk of diabetes among participants in
lifestyle modiﬁcation programs has important implica-
tions for the cost-effectiveness. Those at highest risk of
progressing to type 2 diabetes represent the greatest
potential for absolute reduction of incident cases of type
2 diabetes. A meta-analysis of 30 studies found that
annual rate of progression to diabetes was 10–15% in
those with IGT and IFG, 4.4–6.4% in those with isolated
IGT, and 6.1–9.2% in those with isolated IFG.6 These
values are similar to the estimated annual rate of pro-
gression to type 2 diabetes for those scoring
AUSDRISK≥20 (7.8%). Eligibility requirements for Life!
should therefore include those with IGT, IFG, or both.
On the basis of the results of the Finnish Diabetes
Prevention Study (DPS)28 29 and the US DPP,5 30 the
Life! program was estimated to potentially reduce risk of
progression to type 2 diabetes by 21–39% at 8 months.12
However, these results are not necessarily generalizable
to Life!, as participants in both the Finnish and US
studies had diagnosed IGT. Even if the relative risk
reduction is similar among risk groups, a lower baseline
risk translates to decreased absolute risk reduction and
therefore decreased cost-effectiveness.
A cost-effectiveness analysis is required to assess the
economic implications of various entry requirements
into lifestyle intervention programs. Multiple studies
have reported lifestyle modiﬁcation programs to be cost-
effective in participants with IGT or IFG.31–33 However,
cost-effectiveness of lifestyle modiﬁcation programs has
not been reported in individuals without abnormal
glucose metabolism but nonetheless are at elevated risk
of developing type 2 diabetes.
A limitation of our study is lack of OGTT or HbA1c
data. As stated above, based on the prevalence of IFG
and IGT, the PPV for detecting IGT would be expected
to greater than that for IFG. While there is overlap
between those with IGT and IFG, there remains a signiﬁ-
cant proportion of individuals with IGT who have
normal FPG values.23 Our study therefore does not
wholly evaluate the ability of AUSDRISK to identify indi-
viduals who would beneﬁt from lifestyle modiﬁcation
programs. Further study is warranted on the perform-
ance of AUSDRISK in the detection of IGT, elevated
HbA1c, and undiagnosed diabetes where OGTT and
HbA1c data are available from an Australian population.
This research would complement our current study to
identify a suitable AUSDRISK cut-off score for entry into
Table 3 Characteristics of GGT RFS participants included at different AUSDRISK cut-off values by sex
AUSDRISK cut-off
Males Females
≥12 ≥16 ≥20 ≥12 ≥16 ≥20
Age (years) 62.0 62.8 65.5 61.7 62.4 65.0
Weight (kg) 92.8 99.8 105.1 83.8 89.7 92.4
BMI (kg/m2) 30.3 32.5 34.6 32.2 34.6 36.5
25 to <30 (%) 42.5 29.4 17.0 30.6 21.4 21.7
≥30 (%) 46.6 68.1 83.0 61.1 75.5 78.3
Waist circumference (cm) 106.7 113.3 118.8 100.6 106.6 113.2
Male 94 to <102; female 80 to <88 (%) 18.7 5.6 1.9 4.8 3.1 0.0
Male ≥102; female ≥88 (%) 71.4 92.5 98.1 90.1 94.9 100.0
FPG (mmol/L) 5.5 5.7 5.8 5.4 5.6 5.7
6.1–6.9 (%) 11.2 13.4 20.8 4.4 3.5 10.5
≥7.0 (%) 3.4 5.6 8.3 2.2 5.8 5.3
Total cholesterol (mmol/L) 5.2 5.1 5.0 5.7 5.5 5.3
≥5.5 (%) 42.2 36.9 30.2 56.4 48.0 34.8
HDL (mmol/L) 1.3 1.2 1.2 1.5 1.4 1.4
Male <1.0; female <1.3 (%) 15.7 20.0 20.8 22.6 27.6 34.8
LDL (mmol/L) 3.2 3.0 2.9 3.4 3.2 3.1
≥3.5 (%) 35.4 31.9 26.4 40.9 33.7 13.0
Triglycerides (mmol/L) 1.8 1.9 2.0 1.8 1.9 1.9
≥2.0 (%) 30.3 35.6 41.5 33.7 42.9 43.5
Systolic BP (mm Hg) 141.6 145.2 149.3 139.1 141.1 141.2
≥140 (%) 52.0 59.4 69.8 44.4 50.0 52.2
Diastolic BP (mm Hg) 81.4 83.0 84.0 76.7 76.8 73.4
≥90 (%) 23.1 26.9 28.3 11.9 12.2 4.4
MetS (%) 57.3 71.1 83.3 59.6 70.1 89.5
AUSDRISK, Australian Type 2 Diabetes Risk Assessment Tool; BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose;
GGT RFS, Greater Green Triangle Risk Factor Study; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MetS, metabolic syndrome.
BMJ Open Diabetes Research and Care 2015;3:e000125. doi:10.1136/bmjdrc-2015-000125 5
Epidemiology/health services research
Life! or any subsequent national DPP. Analysis of
AUSDRISK performance in relation to detecting ele-
vated HbA1c levels is particularly signiﬁcant given the
future transition away from performing OGTT and
towards HbA1c and FPG testing.
Data in the GGT RFS was collected in Southwest
Victoria from 2004 to 2006. There were no systematic dif-
ferences in the prevalence of IFG, MetS, and obesity
among age and gender groups to those reported in the
Victorian Health Monitor, a cross-sectional population
health measurement survey collected between May 2009
and April 2010.34 This suggests our sample for the
purpose of these analyses remains a satisfactory indicator
of population health characteristics in Victoria.
This paper has focused exclusively on the perform-
ance of AUSDRISK as a screening tool to identify those
who would beneﬁt from a lifestyle modiﬁcation pro-
grams to prevent type 2 diabetes. It is important to con-
sider that an effective screening method is only one
aspect of implementing lifestyle modiﬁcation programs
to stop or delay the progression to type 2 diabetes.
Lifestyle modiﬁcation programs need to demonstrate
Table 4 Proportion of GGT RFS included at different AUSDRISK cut-off values by age and sex
AUSDRISK cut-off
Age (years) N ≥12 ≥14 ≥16 ≥18 ≥20
Males
40–49 128 23.4 14.1 7.0 1.6 0.0
50–59 184 46.7 32.1 25.0 14.1 4.3
60–69 170 68.2 55.9 42.9 26.5 18.8
70–74 79 78.5 55.7 40.5 26.6 16.5
Total 561 52.4 38.5 28.5 16.8 9.4
Females
40–49 182 14.8 9.3 5.5 0.5 0.5
50–59 189 36.5 21.7 13.8 5.3 2.6
60–69 187 60.4 38.5 22.5 8.0 4.8
70–74 70 61.4 52.9 28.6 12.9 11.4
Total 628 40.1 26.6 15.6 5.6 3.7
Overall
40–49 310 18.4 11.3 6.1 1.0 0.3
50–59 373 41.6 26.8 19.3 9.7 3.5
60–69 357 64.1 46.8 32.2 16.8 11.5
70–74 149 70.5 54.4 34.9 20.1 14.1
Total 1189 45.9 32.2 21.7 10.8 6.4
Population estimates in Victoria, Australia, aged 40–74 years
Number of persons
(000s) (95% CI)
916 (859 to 974) 637 (583 to 690) 425 (379 to 472) 208 (174 to 243) 120 (93 to 146)
Proportion of
population (95% CI)
39.5 (37.0 to 42.0) 27.5 (25.2 to 29.8) 18.3 (16.3 to 20.4) 9.0 (7.5 to 10.5) 5.2 (4.0 to 6.3)
Data are percentages unless otherwise stated.
AUSDRISK, Australian Type 2 Diabetes Risk Assessment Tool; GGT RFS, Greater Green Triangle Risk Factor Study.
Table 5 Characteristics of AUSDRISK using various cut-off values for detecting abnormal fasting glucose
FPG≥6.1 mmol/L
AUSDRISK cut-off Sensitivity Specificity PPV NPV
≥12 81.3 (70.7 to 89.4) 57.7 (54.6 to 60.7) 12.3 (9.5 to 15.5) 97.7 (96.2 to 98.7)
≥13 74.7 (63.3 to 84.0) 63.8 (60.8 to 66.7) 13.1 (10.0 to 16.6) 97.2 (95.6 to 98.3)
≥14 68.0 (56.2 to 78.3) 71.6 (68.7 to 74.3) 14.8 (11.2 to 19.0) 96.8 (95.3 to 98.0)
≥15 61.3 (49.4 to 72.4) 76.4 (73.7 to 79.0) 15.9 (11.9 to 20.7) 96.4 (94.9 to 97.6)
≥16 53.3 (41.4 to 64.9) 81.7 (79.1 to 84.0) 17.5 (12.8 to 23.0) 96.0 (94.5 to 97.2)
≥17 45.3 (33.8 to 57.3) 86.3 (84.1 to 88.4) 19.4 (13.8 to 26.1) 95.6 (94.1 to 96.8)
≥18 34.7 (24.0 to 46.5) 91.7 (89.9 to 93.4) 23.4 (15.9 to 32.4) 95.1 (93.5 to 96.3)
≥19 28.0 (18.2 to 39.6) 94.6 (93.0 to 95.9) 27.3 (17.7 to 38.6) 94.7 (93.2 to 96.0)
≥20 25.3 (16.0 to 36.7) 95.3 (93.9 to 96.5) 28.4 (18.0 to 40.7) 94.6 (93.1 to 95.9)
Data are % (95% CI).
AUSDRISK, Australian Type 2 Diabetes Risk Assessment Tool; FPG, fasting plasma glucose; NPV, negative predictive value; PPV, positive
predictive value.
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effectiveness in reducing the progression to type 2 dia-
betes, and promote sustainable lifestyle changes so that
effects are persistent in the long term. Moreover, lifestyle
modiﬁcation programs represent one part of a targeted
approach to reducing the burden of type 2 diabetes,
that ideally should be accompanied by a range of
population-level approaches to diabetogenic environ-
ments.35 36 Where lifestyle medication programs are not
available, screening individuals for risk of developing
type 2 diabetes remains warranted, provided that simple
lifestyle advice is provided and appropriate follow-up
testing for those at high risk is offered, where
appropriate.
Our ﬁndings indicate that revisiting entry criteria into
Life! is timely. Relying on AUSDRISK at a relatively low
cut-off, while recruiting large numbers of people,
hinders the long-term effectiveness of the program.
A multifaceted approach is required. Initial screening
with AUSDRISK, followed by OGTT, fasting glucose, or
HbA1c for those at high risk to detect IFG, IGT, and
undiagnosed diabetes is needed. Those with IFG and
IGT should be invited into Life!, while those at high risk
but with normal glucose metabolism should be offered
lifestyle information and rescreened in the following
3 years. To reliably establish and justify these thresholds,
economic modeling is required to determine the most
effective strategy.
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